AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35190177
Drug: Nivolumab (N;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (N; 3 mg/kg intravenously on days 1, 15, and 29; n=23)
Trial: 35190177
Drug: Nivolumab with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab with Ipilimumab (NI; 1 mg/kg intravenously on day 1; n=21)
Trial: 35190177
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (chemotherapy or previously untreated patients)
Trial: 35124285
Drug: Constraint-induced movement
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint-induced movement therapy (CIMT)
Trial: 34250977
Drug: Sequential administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential administration of CYD-TDV and quadrivalent HPV vaccine
Trial: 32107364
Drug: Low-dose EC-MPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose EC-MPS
Trial: 32107364
Drug: Standard-dose MZR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose MZR
Trial: 35356618
Drug: Dignity therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dignity therapy (4 weeks intervention)
Trial: 37941050
Drug: Implants
RxNorm normalized name: Goserelin Implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants
Trial: 34129239
Drug: Warfarin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin monotherapy
Trial: 34151820
Drug: Sham group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham group (no active treatment)
Trial: 33504190
Drug: Meta-analysis of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meta-analysis of anticoagulant therapy
Trial: 35355382
Drug: DEX-implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX-implant
Trial: 33850184
Drug: IFNβ1b (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFNβ1b (subcutaneous injections of 8,000,000 IU on days 1, 3, 6)
Trial: 34340527
Drug: THX‐110 (∆9‐THC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THX‐110 (∆9‐THC 10 mg daily and PEA 800 mg daily)
Trial: 32827412
Drug: NR-INF-02 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NR-INF-02 (both doses)
Trial: 34015499
Drug: Polyphenol-rich seaweed
RxNorm normalized name: seaweed extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyphenol-rich seaweed extract (2000 mg/d)
Trial: 35363205
Drug: Online rational
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online rational emotive behavior therapy (online REBT)
Trial: 38775255
Drug: L-arginine
RxNorm normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine
Trial: 35177279
Drug: Topical imiquimod
RxNorm normalized name: imiquimod Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical imiquimod (IMQ) therapy for 16 weeks
Trial: 35091786
Drug: Daily self-monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily self-monitoring of blood pressure (BP) for 2 months
Trial: 35091786
Drug: Multiple self-monitoring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple self-monitoring (BP, body fat, sleeping time, daily step count) for 2 months
Trial: 33100181
Drug: Nivolumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab treatment (low dose regimen, 40 mg)
Trial: 38159908
Drug: Nivolumab treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab treatment
Trial: 35997638
Drug: Control (non-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (non-treatment districts)
Trial: 32306747
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (general practice medical care)
Trial: 37612223
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors
Trial: 34857420
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of bivalent HPV vaccine
Trial: 39773759
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioral therapy (ICBT)
Trial: 34006388
Drug: Nigella sativa
RxNorm normalized name: NIGELLA SATIVA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nigella sativa (NS) oil soft gelatin capsules 450 mg twice daily
Trial: 32349193
Drug: Canagliflozin 100
RxNorm normalized name: canagliflozin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 100 mg (subgroup with preserved LVEF)
Trial: 33209056
Drug: Intravenous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous morphine 0.1 mg/kg
Trial: 35002315
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment).
Trial: 35281316
Drug: YYD601 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YYD601 30 mg
Trial: 35281316
Drug: YYD601 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YYD601 40 mg
Trial: 35281316
Drug: YYD601 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YYD601 60 mg
Trial: 36597163
Drug: Oral chloral
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chloral hydrate 50 mg/kg
Trial: 33462323
Drug: Late implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late implant placement following alveolar ridge preservation (LP/ARP)
Trial: 32998920
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg intravenous dexamethasone
Trial: 34263442
Drug: Danhong Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danhong Injection (DH)
Trial: 32345649
Drug: cRGD-ZW800-1 at
RxNorm normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cRGD-ZW800-1 at 0.05 mg/kg
Trial: 32345649
Drug: cRGD-ZW800-1 at
RxNorm normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cRGD-ZW800-1 at 0.005 mg/kg
Trial: 32345649
Drug: cRGD-ZW800-1 at
RxNorm normalized name: AT-7519
DrugBank: AT-7519 (DB08142)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cRGD-ZW800-1 at 0.015 mg/kg
Trial: 36181015
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.5 mg/kg then 4 mg/kg/h)
Trial: 33825411
Drug: Hemoheal cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoheal cream
Trial: 32220893
Drug: Higher levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher levels of post-induction mAF and post-induction mean mutant molecules per milliliter (mMMPM)
Trial: 35600332
Drug: TCM decoction
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TCM decoction combined with acupuncture and moxibustion (A&M) treatment based on syndrome differentiation and treatment (SDT)
Trial: 34455804
Drug: Isolate treatments
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolate treatments (Sclerotinia sclerotiorum) on fruit inoculation
Trial: 34455804
Drug: Isolate treatments
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolate treatments (Sclerotinia sclerotiorum) on petiole inoculation
Trial: 32954762
Drug: Pulsed radiofrequency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed radiofrequency treatment of suprascapular and axillary nerves
Trial: 32954762
Drug: Nerve block
RxNorm normalized name: Nerve Block Tray 22g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve block treatment of suprascapular and axillary nerves
Trial: 32954762
Drug: Nerve block
RxNorm normalized name: Nerve Block Tray 22g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve block treatment
Trial: 35587063
Drug: Nitazoxanide-based triple
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitazoxanide-based triple therapy (nitazoxanide, proton pump inhibitor, and clarithromycin) for 14 days
Trial: 35587063
Drug: Metronidazole-based standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole-based standard treatment (metronidazole, omeprazole, and clarithromycin) for 14 days
Trial: 35587063
Drug: Nitazoxanide-based triple
RxNorm normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitazoxanide-based triple therapy
Trial: 32030454
Drug: Lavender oil
RxNorm normalized name: Lavender oil
DrugBank: Lavender oil (DB14566)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavender oil inhalation (100% lavender oil for 3 minutes)
Trial: 34048073
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral hygiene education (control group)
Trial: 32678998
Drug: Manualised psychological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manualised psychological treatment for tinnitus, details on dosage and duration not specified.
Trial: 35850126
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of casirivimab and imdevimab
Trial: 36050448
Drug: Trastuzumab (T)
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab (T) + Lapatinib (L)
Trial: 33452180
Drug: MTX +
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX + Etanercept combination therapy
Trial: 35860183
Drug: Algoplaque hydrocolloid
RxNorm normalized name: psyllium hydrocolloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algoplaque hydrocolloid dressing (AHD) combined with nanosilver antibacterial gel
Trial: 32286686
Drug: Sildenafil citrate
RxNorm normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate (25 mg orally twice daily from days 8-12) + Clomiphene citrate (100 mg once daily from days 3-7)
Trial: 32286686
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (100 mg once daily from days 3-7)
Trial: 33485455
Drug: Rituximab (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (1000 mg infusions at 2-week intervals)
Trial: 33485455
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 mg/kg infusions at 4-week intervals)
Trial: 33738615
Drug: Laser acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser acupuncture tele-therapy in addition to methotrexate and aerobic exercise training (group A)
Trial: 32869576
Drug: Flunarizine Hydrochloride,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine Hydrochloride, 5 mg, once daily for 21 days.
Trial: 32861015
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBTI), 4 sessions of behavioral therapy
Trial: 32668505
Drug: Steroid-sparing antiemetic
RxNorm normalized name: ANTIEMETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-sparing antiemetic protocol using olanzapine (group 2)
Trial: 32668505
Drug: Steroid-containing antiemetic
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-containing antiemetic protocol (group 1)
Trial: 33713057
Drug: Intravenous diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diclofenac sodium
Trial: 36459044
Drug: Benson's relaxation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benson's relaxation therapy (BRT) plus aerobic exercise (5 sessions per week) for 8 weeks
Trial: 36459044
Drug: Benson's relaxation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benson's relaxation therapy (BRT) only for 8 weeks
Trial: 33599720
Drug: Ontamalimab 75
RxNorm normalized name: Ontamalimab
DrugBank: Ontamalimab (DB15298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ontamalimab 75 mg every 4 weeks for 72 weeks (OL1)
Trial: 33599720
Drug: Ontamalimab 225
RxNorm normalized name: Ontamalimab
DrugBank: Ontamalimab (DB15298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ontamalimab 225 mg every 4 weeks for 72 weeks (OL1)
Trial: 33599720
Drug: Ontamalimab (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ontamalimab (combined data from both doses)
Trial: 33147220
Drug: Amino acids-mineral
RxNorm normalized name: silk amino acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acids-mineral complexed (AACM) diet with 40, 40 and 2.75 mg/kg of Zn, Mn and Cu, respectively, plus 30, 30 and 5.25 mg/kg of Zn, Mn and Cu from AACM sources
Trial: 35614161
Drug: Observation (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation (no treatment)
Trial: 35385072
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine (266 mg) + bupivacaine hydrochloride (100 mg)
Trial: 35385072
Drug: Bupivacaine hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine hydrochloride (100 mg) alone
Trial: 35084369
Drug: Gabapentin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (300 mg nightly for 3 days and then 300 mg twice a day for 11 days)
Trial: 37186070
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg/day
Trial: 34548324
Drug: No parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No parenteral nutrition
Trial: 33569574
Drug: Intensive anti-hypertensive
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive anti-hypertensive therapy
Trial: 35158064
Drug: 7-day preoperative
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7-day preoperative application of benzoyl peroxide-miconazole nitrate cream
Trial: 32747206
Drug: Intravenous meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous meal administration
Trial: 35968751
Drug: Dexmedetomidine 0
RxNorm normalized name: dexmedetomidine 0.12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0 μg/kg (Control group)
Trial: 35968751
Drug: Dexmedetomidine 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.6 μg/kg (D1 group)
Trial: 34959932
Drug: Astaxanthin (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin (12 mg once daily for 12 weeks)
Trial: 33005007
Drug: Maternal SO2
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal SO2 exposure (per 10 μg/m3 increase)
Trial: 33020985
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and commitment therapy-enhanced cognitive behavioural therapy for insomnia
Trial: 36084965
Drug: allo‐hBM‐MSCDs (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: allo‐hBM‐MSCDs (1 mL, 2 doses)
Trial: 36084965
Drug: allo‐hBM‐MSCs (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: allo‐hBM‐MSCs (1 × 10^6 cells, 1 dose)
Trial: 33278328
Drug: JZP-458 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JZP-458 (25 mg/m2 i.m. and 37.5 mg/m2 i.v.)
Trial: 33278328
Drug: JZP-458 (i.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JZP-458 (i.m. injection)
Trial: 33278328
Drug: JZP-458 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JZP-458 (all dose levels)
Trial: 37646208
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II receptor blockers (ARBs)
Trial: 35491539
Drug: Single ascending
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single ascending dose of Youkenafil Hydrochloride (25, 50, 100, 150, or 200 mg)
Trial: 39675376
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy
Trial: 32379556
Drug: Ozone therapy
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ozone therapy (O3T)
Trial: 35156936
Drug: Weekly monitoring
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly monitoring
Trial: 33975925
Drug: CALLS intervention
RxNorm normalized name: Mosco Corn & Callus Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CALLS intervention (12-weekly phone sessions with patient navigator)
Trial: 36174629
Drug: Niraparib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Niraparib plus ipilimumab (3 mg/kg intravenously every 3 weeks for four doses)
Trial: 34991364
Drug: Proposed interventional
RxNorm normalized name: Propoven
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Proposed interventional treatment in a double-blinded, randomized, placebo-controlled clinical trial
Trial: 32633040
Drug: 2-mm inter-implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-mm inter-implant distance
Trial: 35351381
Drug: Midazolam (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.5 mg/kg)
Trial: 34910380
Drug: BSC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSC plus a moisturising cream
Trial: 33149205
Drug: Albendazole 400
RxNorm normalized name: albendazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole 400 mg/day for three consecutive days
Trial: 32486104
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Etoricoxib + exercise)
Trial: 32613089
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment only
Trial: 33051719
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid infiltrated tumescent solution (0.1%)
Trial: 34933842
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day of full-spectrum hyaluronan (FS-HA)
Trial: 36344917
Drug: Bupivacaine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine + 1 µg/kg dexmedetomidine
Trial: 36344917
Drug: Bupivacaine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine + 1 µg/kg fentanyl
Trial: 39340109
Drug: All vaccines
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All vaccines
Trial: 34984792
Drug: Omalizumab 300
RxNorm normalized name: OMALIZUMAB 300MG/2ML INJ,SOLN,SYR,2ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab 300 mg (OMA300)
Trial: 34984792
Drug: Omalizumab 150
RxNorm normalized name: omalizumab 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab 150 mg (OMA150)
Trial: 33660386
Drug: Homeopathic Treatment
RxNorm normalized name: homeopathic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic Treatment as an Add-On Therapy
Trial: 35672726
Drug: Combination condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination condition (30% price increase + information nudge)
Trial: 36498690
Drug: Instrument-Assisted Manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instrument-Assisted Manual Therapy (IAMT)
Trial: 33617382
Drug: Current therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current therapy satisfaction
Trial: 34244006
Drug: RV3 rotavirus
RxNorm normalized name: ROTAVIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV3 rotavirus vaccine (Bio Farma) in neonates
Trial: 34244006
Drug: RV3 rotavirus
RxNorm normalized name: ROTAVIRUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RV3 rotavirus vaccine (Bio Farma) in adults and children
Trial: 33600060
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 2 g/kg IVIG once
Trial: 32068688
Drug: NT-814 50
RxNorm normalized name: NT-219
DrugBank: NT-219 (DB17490)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-814 50 mg
Trial: 32068688
Drug: NT-814 150
RxNorm normalized name: NT-219
DrugBank: NT-219 (DB17490)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-814 150 mg
Trial: 32068688
Drug: NT-814 300
RxNorm normalized name: NT-219
DrugBank: NT-219 (DB17490)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-814 300 mg
Trial: 34806658
Drug: i.v. lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. lidocaine (1.5 mg/kg later 2 mg/kg/hour)
Trial: 32976331
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and visual education with photographs (in-person)
Trial: 32976331
Drug: Oral only
RxNorm normalized name: TABLET, ORAL ONLY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral only education
Trial: 35669353
Drug: Ivermectin 24
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin 24 mg (Iv24)